# Atomoxetine

## apo-ATOMOXETINE 25mg

#### 一般可用

| 藥品代碼       | OATM25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Attention deficit hyperactivity disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量       | 6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day， whichever is less 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; MAX 100 mg daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 禁忌           | Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用         | Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism |
| 孕期用藥建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## apo-Atomoxetine 18mg

| 藥品代碼       | OATMX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Attention deficit hyperactivity disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量       | 6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; MAX 1.4 mg/kg daily or 100 mg/day， whichever is less 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; MAX 100 mg daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 禁忌           | Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用         | Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism |
| 孕期用藥建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Strattera 10mg

#### 一般可用

| 藥品代碼       | OSTR1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量       | Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 禁忌           | with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 副作用         | Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ) |
| 孕期用藥建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Strattera 25mg

#### 一般可用

| 藥品代碼       | OSTR2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量       | Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 禁忌           | with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 副作用         | Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ) |
| 孕期用藥建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## STRATTERA 40MG

#### 一般可用

| 藥品代碼       | OSTR4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量       | Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 禁忌           | with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 副作用         | Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ) |
| 孕期用藥建議   | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Strattera 60mg

#### 限交付調劑

| 藥品代碼       | OSTR6                                                                                                                                                                                                                                                                                                                                                                                                                |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                        |
| 用法用量       | Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg. |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                         |
| 禁忌           | with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                    |
| 副作用         | Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence.                                                                                                                                                                                                                                                                                                                                      |
| 孕期用藥建議   | nan                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                 |

